Differentialdiagnose der Gelenksentzündungen, Kollagenosen

Psenak, O; PMU-Lehre für 3. Jahrgang:_x000D_ Pathophysiologische des muskuloskelettalen Apparates; 04.10.2011; Salzburg. 2011.

Orencia Kasuistiken

Psenak, O; ACTION-Investigatormeeting Kasuistiken; 25.11.2011; Anif. 2011.

Kollagenosen

Psenak, O; Fortbildungsseminar für Turnusärzte SALK; 11.01.2011; Salzburg. 2011.

S1-2: Long-Term Follow-Up in ABCSG-12: Significantly Improved Overall Survival with Adjuvant Zoledronic Acid in Premenopausal Patients with Endocrine-Receptor–Positive Early Breast Cancer._x000D_

Gnant, M; Mlineritsch, B; Luschin-Ebengreuth, G; Stoeger, H; Dubsky, P; Jakesz, R; Singer, C, Eidtmann, H; Fesl, C; Eiermann, W; Marth, C; Greil, R; Cancer Research, 24 Supplement_x000D_ _x000D_ . 2011. 71: 1-2.

Bedeutung des RANK / RANK-Ligand Systems beim Mammakarzinom: Biologische Grundlagen.

Ressler, S; Mlineritsch, B; Greil, R; Universum Innere Medizin. 2011.

VEGF, PARP, mTOR, EGFR und PI3K beim HER2-negativen Mammakarzinom

Gampenrieder, SP; Mlineritsch, B; Greil, R. Universum für Innere Medizin 2011. 2011. 4: 79-80.

S4-8: First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H)+ docetaxel (DOC) as first-line therapy for HER2− positive locally recurrent/metastatic breast cancer (LR/mBC)_x000D_

Gianni, L; Romieu, G; Lichinitser, M; Serrano, S; Mansutti, M Pivot, X; Smirnova, I; Moliterni, A; Andre, F; Chan, A; Lipatov, O; Chan, S; Wardley, A; Greil, R; Provencher, L; Moore, N; Prot, S; Semiglazov, V; Cancer Research, 24 Supplement_x000D_ . 2011. 71: 4-8.

Bisphosphonate in der Therapie des Mammakarzinoms

Ressler, S; Mlineritsch, B; Greil, R; MEDIUM. 2011. 3: 26-30.

Parp Inhibitoren

Ressler, S; Mlineritsch, B; Greil, R; Universum Innere Medizin. 2011.

Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools

Merkel, O; Hamacher, F; Sifft, E; Kenner, L; Greil, R MOL CANCER THER. 2011; 10(7): 1127-1136.